Leadership with a clear vision for success
Petauri Health Mission
To ensure that scientific breakthroughs reach patients with unmet medical needs, by providing seamlessly integrated commercialization solutions.
Petauri Health Vision
To improve patient outcomes by speeding access to life-changing healthcare innovations.
Petauri Health Senior Leadership Team
Dan Renick
John Zimmerman
MRIDUL MALHOTRA
John Zimmerman
CFO & COO, Petauri Health
In addition to his leadership role at Petauri Health, John Zimmerman is also a Partner at Oak Hill Capital, where he is responsible for Portfolio Company operations, and sits on the firm’s Investment Committee. Prior to partnering with Oak Hill as a Senior Advisor in 2015, John served as the CFO and a Board Director of Tomkins plc, a global engineering and manufacturing group and parent company of the Gates Corporation, the leading global manufacturer of power transmission belts and a global manufacturer of fluid power products. John has more than 20 years of experience in senior operating or finance roles within Tomkins plc and its subsidiaries. He is a Chartered Accountant (SA) and earned a BCom degree from the University of Cape Town.
Dan Renick
CEO, Petauri Health
A well-known executive in the life sciences industry, Dan Renick has more than 28 years of healthcare experience. He provides visionary leadership to life sciences innovators with highly effective, strategic, and pragmatic solutions to commercialization challenges. As CEO of Petauri Health, he is applying this experience in partnership with clients to ensure that scientific breakthroughs reach patients with unmet medical needs through Petauri's data-driven, digital-forward expert solutions.
Prior to forming Petauri Health in partnership with Oak Hill Capital Partners, Dan was a founding executive and President of Precision Value & Health following their acquisition of Hobart Group Holdings in 2013. Under Dan’s leadership, Precision Value & Health experienced outsized organic growth, completed numerous strategic acquisitions, and received multiple industry awards and accolades.
At Humana, Inc., Dan served as Director of Corporate Pharmacy Management. In this role, he was responsible for pharmacy programs and trade relations, including oversight of contracting with pharmaceutical companies and pharmacy provider organizations. Dan also held the position of National Director of Pharmacy Networks, partnering with pharmacy channel stakeholders to improve access and quality in a cost-efficient manner. Earlier in his career, Dan was a Corporate Account Executive at Merck, working with large employers, business coalitions, and benefits consultants to facilitate rational, evidence-based healthcare decisions.
Dan has consistently been recognized as an industry leader, including: Top 10 Innovation Catalyst by Medical Marketing and Media (MM&M); PM360 ELITE Transformational Leader award winner, which recognizes 100 of the most influential people in the healthcare industry; strategic industry leader recognition by American Healthcare Leader; and featured by Pharmaceutical Commerce, among others.
Dan received a pharmacy degree from the University of Kentucky and a BS in chemistry and biology from Western Kentucky University.
Mridul Malhotra
CSO and Global Head: Evidence, Value, and Access (EVA), Petauri Health
A highly-regarded market access leader and growth catalyst, Mridul has a passion for growing teams, service lines, and enterprises from the ground up. With over 13 years of business-development experience and an exceptional track record of building companies, Mridul brings progressive leadership skills in talent identification, acquisition, development, and retention.
As Petauri’s Chief Strategic Officer (CSO) and Global Head: Evidence, Value, and Access (EVA), Mridul’s priorities are to develop strategic acquisition and partnership opportunities, leveraging his deep relationships in the market access space, while establishing Petauri’s global EVA group as a partner to clients across the company’s service offerings.
Mridul reports to Petauri CEO, Dan Renick. They previously worked together at Precision Value & Health to address clients’ value and access business objectives where Mridul built a world-class pricing and market access consultancy from the ground up, leading the first phase of organic growth through double-digit revenue year-over-year.
Just prior to joining Petauri Health, Mridul was Managing Partner at Clarivate, leading a global team of over 200 consultants specializing in commercial strategy, pricing and market access, and health economics and outcomes research (HEOR). Prior to his time at Precision, Mridul developed a novel service offering at Quintiles, which had the fastest revenue trajectory of all of the company’s offerings, and, at ICON/PriceSpective, built the company’s second largest standalone office.
Petauri Health Board of Directors
Petauri is very proud to partner with Oak Hill Capital. Oak Hill is a long-standing private equity firm focused on the North America middle market. The firm implements a highly systematic approach to theme development, proactive origination, and value creation in partnership with management to build franchises of lasting value. Since 1986, Oak Hill and its predecessors have raised approximately $20 billion of initial capital commitments and co-investments, invested in approximately 100 companies, and completed more than 300 add-on acquisitions, representing an aggregate enterprise value at acquisition of over $60 billion.
Dan Renick
Micah Meisel
Brian Cherry
Peter Armstrong
Dan Renick
CEO, Petauri Health
Dan Renick brings more than 28 years of healthcare knowledge and executive experience to his role as CEO of Petauri Health. Dan also serves as a member of the Petauri Health Board of Directors. A proven leader with extensive private equity experience, Dan provides visionary leadership to life sciences innovators with highly effective, strategic, and pragmatic solutions to commercialization challenges. Previously, Dan was a founding executive and President of Precision Value & Health, following their acquisition of Hobart Group Holdings, in 2013. Under Dan’s leadership, Precision Value & Health experienced outsized organic growth, completed numerous strategic acquisitions, and received multiple industry awards.
He is also cofounder of Quantuvis and a current member of its Board of Directors. Quantuvis is the market leader in comprehensive software solutions for life sciences companies and payers, partnering with them to create value and innovation while addressing affordability.
Micah Meisel
Partner, Oak Hill Capital
As the leader of Oak Hill Capital’s healthcare team, Micah Meisel brings broad-based healthcare experience to the Petauri Health Board of Directors. As Partner at Oak Hill Capital, he is responsible for originating, structuring, and managing investments in the healthcare sector. Prior to joining Oak Hill, Micah was a Managing Director at InTandem Capital Partners and a Managing Director at J.H. Whitney & Co. Prior to that he was a Senior Associate at Oliver Wyman and an Associate in the leveraged finance group at J.P. Morgan. Micah earned a BA from Tufts University and an MBA from the Tuck School of Business at Dartmouth, where he was an Edward Tuck Scholar.
Brian Cherry
Managing Partner, Oak Hill Capital
As Managing Partner at Oak Hill Capital, Brian Cherry has a long-standing track record of identifying quality companies in which to invest and influencing their growth and development.
Prior to joining Oak Hill in 2014, Brian was a Senior Managing Director at J.H. Whitney & Co. Prior to that, he was a member of the merchant banking group at Donaldson, Lufkin & Jenrette, Inc. Brian earned an AB from Princeton University and an MBA from the Wharton School of the University of Pennsylvania.
Peter Armstrong
Principal, Oak Hill Capital
Peter Armstrong is a Principal of Oak Hill Capital. Peter has been with the firm since 2012 and is a member of the healthcare team. Prior to joining Oak Hill, he was a member of the mergers and acquisitions group at Lazard Frères & Co. Peter earned a BA from the University of Pennsylvania. He holds a Chartered Financial Analyst designation.
For more information, please visit oakhill.com